GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
The therapeutic candidate is under development for the treatment of cardiovascular diseases, musculoskeletal injuries and degeneration, aging frailty and osteoarthritis. It consists of allogeneic bone marrow derived mesenchymal stromal cells (MSCs) administered through intravenous and intraarticular route.
For a complete picture of StromaForte’s drug-specific PTSR and LoA scores, buy the report here.
#StromaForte #Swedish #StromaBio #Cardiovascular #Disease #Likelihood #Approval